Larry Biegelsen
Stock Analyst at Wells Fargo
(3.75)
# 733
Out of 5,146 analysts
367
Total ratings
54.62%
Success rate
6.25%
Average return
Main Sectors:
Stocks Rated by Larry Biegelsen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BLCO Bausch + Lomb | Maintains: Equal-Weight | $17 → $18 | $18.60 | -3.23% | 10 | Feb 19, 2026 | |
| AXGN Axogen | Initiates: Overweight | $40 | $31.22 | +28.12% | 1 | Feb 19, 2026 | |
| GKOS Glaukos | Maintains: Overweight | $122 → $135 | $120.89 | +11.67% | 18 | Feb 18, 2026 | |
| DXCM DexCom | Maintains: Overweight | $93 → $85 | $73.16 | +16.18% | 11 | Feb 13, 2026 | |
| INSP Inspire Medical Systems | Downgrades: Equal-Weight | $145 → $70 | $59.25 | +18.14% | 16 | Feb 12, 2026 | |
| ZBH Zimmer Biomet Holdings | Maintains: Equal-Weight | $93 → $98 | $99.85 | -1.85% | 11 | Feb 11, 2026 | |
| EW Edwards Lifesciences | Maintains: Overweight | $96 → $100 | $83.40 | +19.90% | 19 | Feb 11, 2026 | |
| GEHC GE HealthCare Technologies | Maintains: Overweight | $95 → $97 | $84.03 | +15.43% | 6 | Feb 5, 2026 | |
| BSX Boston Scientific | Maintains: Overweight | $125 → $94 | $73.48 | +27.93% | 16 | Feb 5, 2026 | |
| TFX Teleflex | Maintains: Equal-Weight | $139 → $116 | $111.89 | +3.67% | 9 | Jan 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $38 | $23.00 | +65.22% | 1 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $230 → $240 | $245.17 | -2.11% | 15 | Jan 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $374 | $338.67 | +10.43% | 20 | Jan 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $28 | $25.29 | +10.72% | 3 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $72 → $82 | $83.47 | -1.76% | 20 | Dec 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $114 | $96.65 | +17.95% | 19 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $452 → $456 | $384.03 | +18.74% | 17 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $103 → $95 | $79.23 | +19.90% | 12 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $13 → $14 | $26.01 | -46.17% | 11 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $9 → $10 | $8.81 | +13.51% | 16 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $599 → $600 | $506.17 | +18.54% | 21 | Oct 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $0.68 → $0.85 | $1.15 | -26.09% | 6 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Equal-Weight | $93 | $86.27 | +7.80% | 9 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $6 → $3 | $1.63 | +84.05% | 7 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $33 → $24 | $20.73 | +15.77% | 17 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $40 → $15 | $14.99 | -3.27% | 18 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $17 | $14.72 | +15.49% | 1 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $40 → $49 | $11.59 | +322.78% | 2 | Dec 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $136 | $114.76 | +18.51% | 21 | Apr 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $70 | $96.22 | -27.25% | 7 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $279 → $270 | $180.96 | +49.20% | 5 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $75.72 | - | 2 | Nov 2, 2017 |
Bausch + Lomb
Feb 19, 2026
Maintains: Equal-Weight
Price Target: $17 → $18
Current: $18.60
Upside: -3.23%
Axogen
Feb 19, 2026
Initiates: Overweight
Price Target: $40
Current: $31.22
Upside: +28.12%
Glaukos
Feb 18, 2026
Maintains: Overweight
Price Target: $122 → $135
Current: $120.89
Upside: +11.67%
DexCom
Feb 13, 2026
Maintains: Overweight
Price Target: $93 → $85
Current: $73.16
Upside: +16.18%
Inspire Medical Systems
Feb 12, 2026
Downgrades: Equal-Weight
Price Target: $145 → $70
Current: $59.25
Upside: +18.14%
Zimmer Biomet Holdings
Feb 11, 2026
Maintains: Equal-Weight
Price Target: $93 → $98
Current: $99.85
Upside: -1.85%
Edwards Lifesciences
Feb 11, 2026
Maintains: Overweight
Price Target: $96 → $100
Current: $83.40
Upside: +19.90%
GE HealthCare Technologies
Feb 5, 2026
Maintains: Overweight
Price Target: $95 → $97
Current: $84.03
Upside: +15.43%
Boston Scientific
Feb 5, 2026
Maintains: Overweight
Price Target: $125 → $94
Current: $73.48
Upside: +27.93%
Teleflex
Jan 29, 2026
Maintains: Equal-Weight
Price Target: $139 → $116
Current: $111.89
Upside: +3.67%
Jan 28, 2026
Initiates: Overweight
Price Target: $38
Current: $23.00
Upside: +65.22%
Jan 22, 2026
Maintains: Overweight
Price Target: $230 → $240
Current: $245.17
Upside: -2.11%
Jan 15, 2026
Downgrades: Equal-Weight
Price Target: $374
Current: $338.67
Upside: +10.43%
Dec 12, 2025
Maintains: Overweight
Price Target: $27 → $28
Current: $25.29
Upside: +10.72%
Dec 5, 2025
Maintains: Equal-Weight
Price Target: $72 → $82
Current: $83.47
Upside: -1.76%
Nov 19, 2025
Maintains: Overweight
Price Target: $100 → $114
Current: $96.65
Upside: +17.95%
Nov 14, 2025
Maintains: Overweight
Price Target: $452 → $456
Current: $384.03
Upside: +18.74%
Nov 14, 2025
Maintains: Overweight
Price Target: $103 → $95
Current: $79.23
Upside: +19.90%
Nov 7, 2025
Maintains: Equal-Weight
Price Target: $13 → $14
Current: $26.01
Upside: -46.17%
Nov 6, 2025
Maintains: Equal-Weight
Price Target: $9 → $10
Current: $8.81
Upside: +13.51%
Oct 22, 2025
Maintains: Overweight
Price Target: $599 → $600
Current: $506.17
Upside: +18.54%
Aug 15, 2025
Maintains: Equal-Weight
Price Target: $0.68 → $0.85
Current: $1.15
Upside: -26.09%
Aug 6, 2025
Reinstates: Equal-Weight
Price Target: $93
Current: $86.27
Upside: +7.80%
Aug 1, 2025
Maintains: Equal-Weight
Price Target: $6 → $3
Current: $1.63
Upside: +84.05%
Aug 1, 2025
Maintains: Equal-Weight
Price Target: $33 → $24
Current: $20.73
Upside: +15.77%
Jul 25, 2025
Downgrades: Equal-Weight
Price Target: $40 → $15
Current: $14.99
Upside: -3.27%
Jan 30, 2025
Maintains: Overweight
Price Target: $13 → $17
Current: $14.72
Upside: +15.49%
Dec 5, 2023
Upgrades: Overweight
Price Target: $40 → $49
Current: $11.59
Upside: +322.78%
Apr 5, 2023
Maintains: Overweight
Price Target: $140 → $136
Current: $114.76
Upside: +18.51%
May 11, 2022
Maintains: Overweight
Price Target: $80 → $70
Current: $96.22
Upside: -27.25%
Apr 8, 2020
Maintains: Overweight
Price Target: $279 → $270
Current: $180.96
Upside: +49.20%
Nov 2, 2017
Upgrades: Outperform
Price Target: n/a
Current: $75.72
Upside: -